Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2020-09-08 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
中天国富证券有限公司关于哈药股份2020年半年度持续督导意见
Audit Report / Information Classification · 95% confidence The document is titled as a "2020年半年度持续督导意见" which translates to "2020 Semi-Annual Continuous Supervision Opinion" related to a takeover bid (要约收购) by 哈药集团有限公司 for 哈药集团股份有限公司. It is issued by 中天国富证券有限公司 as the financial advisor. The document covers the period from January 1, 2020 to June 30, 2020, and discusses compliance with laws, fulfillment of public commitments, operational independence, and other supervisory matters during the takeover process. It is a detailed supervisory opinion report issued mid-year, focusing on the takeover and related governance and compliance issues. This type of document is not a full annual or interim financial report, nor is it a simple announcement or voting result. It is a specialized report related to ongoing supervision during a takeover bid, which aligns with the category of Audit Report / Information (AR) as it involves regulatory compliance, supervisory opinions, and audit-like oversight during the takeover period. The document length (7341 characters) and content confirm it is a substantive report, not just an announcement or certification. Therefore, the best fitting classification is AR (Audit Report / Information). H1 2020
2020-09-08 Chinese
关于2020年上半年获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1190 characters) about government subsidies received by the company during the first half of 2020. It provides details on the amounts and types of subsidies but does not contain comprehensive financial statements or detailed financial analysis. It is an announcement of a specific event (receipt of government grants) rather than a full financial report or audit. The document is not a full interim report or annual report, nor is it a certification or regulatory filing in the strict sense. Given its nature as a brief announcement about government subsidies related to the half-year period, it fits best under Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2020-08-25 Chinese
2020年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2020 年半年度报告' which translates to '2020 Semi-Annual Report'. It contains detailed financial data, business overview, management discussion and analysis, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2020 to June 30, 2020, which is a half-year period. It includes financial statements, management analysis, business segments, and risk disclosures. The length of the document is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an annual report (10-K) or a full year report, nor is it a simple earnings release or presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-25 Chinese
2020年半年度报告摘要
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2020 年半年度报告摘要" which translates to "2020 Half-Year Report Summary." It contains detailed financial data for the first half of 2020, including total assets, net profit, earnings per share, and cash flow figures. It also includes a comprehensive discussion and analysis of the company's operating conditions, industry trends, and future plans. The document is over 6,000 characters long and contains substantive financial data and management discussion, which fits the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a full report summary with financial statements and analysis for a period shorter than a full fiscal year (half-year). Therefore, the appropriate classification is IR. H1 2020
2020-08-25 Chinese
独立董事关于计提资产减值准备的独立意见
Audit Report / Information Classification · 95% confidence The document is a statement from independent directors regarding the asset impairment provision for the first half of 2020. It references compliance with accounting standards and company policies, and provides an independent opinion approving the asset impairment provision. The document is short (602 characters) and primarily contains an independent director's opinion rather than detailed financial data or a full audit report. It does not contain comprehensive financial statements or detailed audit findings. Therefore, it is best classified as an Audit Report / Information (AR), which includes standalone audit opinions and accounting principle applications, rather than a full Annual Report or Interim Report. H1 2020
2020-08-25 Chinese
关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the provision for asset impairment for the first half of 2020. It details the amounts of bad debt provision, inventory write-downs, and dividend receivable impairment, along with the impact on the company's profit. It includes opinions from the board, independent directors, and the supervisory board confirming the appropriateness and compliance of the impairment provision. The document is relatively short (1274 characters) and is an announcement of a specific accounting action rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). It is also not a certification or a regulatory compliance filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-08-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.